Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
CadalminTM ADe is an anti-diabetic nutraceutical, which is effective to combat type-2 diabetes
A patent has been granted to Kochi based Central Marine Fisheries Research Institute (CMFRI) for an invention entitled A process to prepare antidiabetic concentrates from seaweeds and a product thereof (Patent Number 346531) for the term of 20 years from the 19th day of October 2015 in accordance with the provisions of the Patents Act, 1970.
CadalminTM ADe is an anti-diabetic nutraceutical, which is effective to combat type-2 diabetes. It contains 100% natural marine bioactive ingredients extracted from selected seaweeds.
The bioactive ingredients in CadalminTM ADe competitively inhibit dipeptidyl peptidase-IV and tyrosine phosphatase 1B. The active ingredients of the product decreases production of various mediators responsible for inducing type-2 diabetes, and interfere with the release of simple sugars from the gut, which reduces postprandial hyperglycemia thereby hindering the occurrence of type-2 diabetes.
CadalminTM ADe has no side effects as proved from the long-term toxicity studies. The active ingredients purified and concentrated; a total of 350 mg active ingredients in the product are packed in plant-based capsules (cellulose-based hypermelose) to meet the dietary needs of vegetarians.
The technology has been transfered to Pioneer Pharmaceuticals Limited in Kochi for commercial production and marketing.